CN113430270A - Application of immune related gene in renal cancer prognosis prediction - Google Patents
Application of immune related gene in renal cancer prognosis prediction Download PDFInfo
- Publication number
- CN113430270A CN113430270A CN202110731571.2A CN202110731571A CN113430270A CN 113430270 A CN113430270 A CN 113430270A CN 202110731571 A CN202110731571 A CN 202110731571A CN 113430270 A CN113430270 A CN 113430270A
- Authority
- CN
- China
- Prior art keywords
- prognosis
- gene
- genes
- biomarker
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 67
- 208000008839 Kidney Neoplasms Diseases 0.000 title claims abstract description 52
- 206010038389 Renal cancer Diseases 0.000 title claims abstract description 52
- 201000010982 kidney cancer Diseases 0.000 title claims abstract description 52
- 238000004393 prognosis Methods 0.000 title claims abstract description 51
- 230000004083 survival effect Effects 0.000 claims abstract description 42
- 101000711744 Homo sapiens Non-secretory ribonuclease Proteins 0.000 claims abstract description 16
- 101000712600 Homo sapiens Thyroid hormone receptor beta Proteins 0.000 claims abstract description 16
- 102100034217 Non-secretory ribonuclease Human genes 0.000 claims abstract description 16
- 108010002687 Survivin Proteins 0.000 claims abstract description 16
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 claims abstract description 16
- 102000000763 Survivin Human genes 0.000 claims abstract description 15
- 239000000090 biomarker Substances 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 239000000523 sample Substances 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 239000012502 diagnostic product Substances 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 238000010837 poor prognosis Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 238000002123 RNA extraction Methods 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000010839 reverse transcription Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000011223 gene expression profiling Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 13
- 238000004458 analytical method Methods 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 238000012549 training Methods 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 6
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 5
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000000611 regression analysis Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000032818 Microsatellite Instability Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 101150115284 BIRC5 gene Proteins 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101150039659 RNASE2 gene Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 1
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007812 electrochemical assay Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 108700021357 erbA Genes Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 231100001158 immune-related toxicity Toxicity 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 238000012174 single-cell RNA sequencing Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 101150072448 thrB gene Proteins 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000007817 turbidimetric assay Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Data Mining & Analysis (AREA)
- Immunology (AREA)
- Databases & Information Systems (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Primary Health Care (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Evolutionary Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses application of immune-related genes in kidney cancer prognosis prediction, and particularly relates to immune-related genes BIRC5, RNASE2 and THRB. The invention proves that the BIRC5, the RNASE2 and the THRB are related to the survival of the renal cancer patient through single-factor Cox analysis, and can be used for predicting the survival period of the renal cancer patient and monitoring the disease progress of the patient, thereby guiding the clinical treatment of individuals.
Description
Technical Field
The invention relates to the field of disease diagnosis, in particular to application of immune related genes in prognosis prediction of kidney cancer.
Background
Renal cancer (RCC) is one of the most common malignancies of the urinary system and is classified into multiple subtypes according to histological classification, with Clear Cell Carcinoma (CCRCC) being the major subtype of kidney cancer, accounting for about 75-80% of kidney cancer (Pavlovich CP, Schmidt LS, Phillips JL. the genetic basic side of Renal Cell Carcinoma [ J ]. Urol Clin North Am, 2003,30(3):437-54, vii.), other types including papillary Carcinoma, chromophobe Carcinoma, Bellini canal (collecting canal) Carcinoma, etc. Patients with renal clear cell carcinoma had the highest mortality and metastasis rates, with about 400,000 new cases of renal clear cell carcinoma worldwide in 2018, and 175,000 cases of death (Lindenberg L, Mena E, Choyke PL, et al. pet imaging in secondary cancer [ J ]. Curr Opin Oncol,2019,31(3):216 + 221.). The predominant mode of treatment for renal clear cell carcinoma is surgical resection, but patients receiving resection have a postoperative recurrence rate of up to 40% or more (Rossi SH, Klatte T, Usher-Smith J, et al. epidemiology and screening for renal cancer [ J ]. World J Urol, 2018,36(9): 1341-1353.). Renal clear cell carcinoma has no obvious characteristics in the early stage, and lacks an effective diagnosis method and an early warning signal, about 30 percent of patients have long-term metastasis when being treated for the first time, and the 5-year survival rate is reduced from 90 percent to 12 percent (Campbell S, Uzzo RG, Allaf ME, et al. Renal Mass and Localized Renal Cancer: AUAGuideline [ J ] J Urol,2017,198(3): 520-529.).
The tumor immunotherapy is an innovative cancer treatment method after surgical treatment, chemotherapy, radiotherapy and targeted treatment, and has the action mechanism of enhancing the anti-tumor immune response of an organism by activating immune cells in vivo, specifically eliminating tumor tiny residual focuses, inhibiting tumor growth, breaking immune tolerance and achieving the purpose of controlling and killing tumor cells. The traditional cancer treatment method can not only kill tumor cells, but also cause unnecessary damage to normal tissue cells of the body, influence the physical condition of patients and ensure the treatment effect difficultly. With the development of the disciplines of molecular biology, medical immunology and the like, the tumor immunotherapy is more and more mature, and has made a major breakthrough in the treatment of malignant tumors such as melanoma, acute lymphatic leukemia, lung cancer and the like (Cuevas LM, Daud AI. immunotherapy for melanoma [ J ]. Semin Cutan Med Surg,2018,37(2): 127-.
The kidney cancer is a tumor with stronger immunogenicity, and the immunogenicity enables the kidney cancer to have wide immunotherapy prospect. Although immunotherapy has made great progress in the treatment of kidney Cancer, not all patients can benefit from it, there are problems with some patients not responding to immune checkpoint inhibitor treatment, some patients not developing Resistance long after dosing, and immune-related toxicity (Nowick TS, Hu-Lieskovan S, Ribas A. mechanism of Resistance PD-1and PD-L1 Block [ J ]. Cancer J, 2018,24(1): 47-53.). Therefore, there is a need to develop new effective immunotherapy targets, which can increase the efficacy and reduce the side effects by combination therapy and the like. With the increasing understanding of the immune microenvironment of renal cancer gene combination by next-generation sequencing, treatment selection can be guided by starting from renal cancer genome characteristics, so that the development of precise medicine is advanced, and therefore, better understanding of the molecular mechanism and immune microenvironment of the disease and recognition of better prognostic biomarkers and prediction models are urgently needed.
Disclosure of Invention
The object of the present invention is to provide a biomarker panel, a diagnostic product, a device and an apparatus for the prognosis of kidney cancer.
In order to achieve the above objects, the present invention provides, in a first aspect, a biomarker population for the prognosis of kidney cancer, the biomarker population comprising BIRC5, RNASE2 and/or THRB.
In a second aspect, the present invention provides the use of a reagent for detecting a biomarker population according to the first aspect of the present invention in a sample for the preparation of a diagnostic product for the prognosis of renal cancer.
Further, the reagent comprises a reagent for detecting the expression level of the biomarker in the sample by a digital imaging technology, a protein immunization technology, a dye technology, a nucleic acid sequencing technology, a nucleic acid hybridization technology, a chromatographic technology and a mass spectrometry technology.
Further, the sample is selected from the group consisting of: peripheral blood samples, serum samples, plasma samples, urine samples, saliva samples, and tissue samples.
In a third aspect, the present invention provides a diagnostic product for the prognosis of renal cancer, the diagnostic product comprising reagents for detecting the biomarker panel according to the first aspect of the present invention.
Further, the diagnostic product comprises a chip and a kit.
Further, the reagents include reagents that detect the amount of RNA transcribed from the biomarker panel genes.
Further, the reagent is a reagent that detects the amount of mRNA transcribed from the biomarker population.
Further, the reagent is a reagent for detecting the amount of cDNA complementary to mRNA transcribed from the gene.
Further, the reagent includes a probe or a primer.
Furthermore, the diagnostic product also comprises a total RNA extraction reagent, a reverse transcription reagent and/or a second generation sequencing reagent.
Further, the reagent is a reagent for detecting the amount of the polypeptide/protein encoded by the biomarker group gene.
Further, the reagent is an antibody, an antibody fragment, or an affinity protein.
The fourth aspect of the present invention provides a renal cancer survival prediction apparatus, including:
a data acquisition module, configured to acquire gene expression profile data of the biomarker group according to the first aspect of the present invention from a cancer patient to be detected;
a prediction module for providing the gene expression profile data as input to a trained prediction model trained to predict a life span of a cancer patient based on gene expression profile data of the cancer patient;
and the prediction result acquisition module is used for acquiring the output of the prediction model to obtain the life cycle prediction result of the cancer patient to be detected.
Further, the prediction model is a Cox regression model.
Further, the Cox regression model is a LASSO Cox regression model.
Further, the formula of the prediction model isWherein N is the number of genes used for predicting prognosis, Expi is the expression level of each gene, and Ci is the regression coefficient of each gene; when the risk score is higher, the patient has a poor prognosis; when the risk score is low, the patient prognosis is good.
Further, the genes were BIRC5, RNASE2 and THRB.
Further, the C1, C2 and C3 are respectively 0.425, 0.1117 and-0.7094.
A fifth aspect of the present invention provides a computer device comprising a memory and a processor, the memory storing a program, the processor implementing the following method when executing the program:
obtaining gene expression profile data of a biomarker panel according to the first aspect of the present invention from a cancer patient to be tested;
providing the gene expression profile data as input to a trained prediction model;
and outputting the survival period prediction result of the cancer patient to be detected.
Further, the prediction model is a Cox regression model.
Further, the Cox regression model is a LASSO Cox regression model.
Further, the formula of the prediction model isWherein N is the number of genes used for predicting prognosis, Expi is the expression level of each gene, Ci is the regression coefficient of each gene, and when the risk score is higher, the prognosis of the patient is poor; when the risk score is low, the patient prognosis is good.
Further, the genes were BIRC5, RNASE2 and THRB.
Further, the C1, C2 and C3 are respectively 0.425, 0.1117 and-0.7094.
A sixth aspect of the present invention provides a computer-readable storage medium having stored thereon a program which, when executed, implements a method of:
obtaining gene expression profile data of a biomarker panel according to the first aspect of the present invention from a cancer patient to be tested;
providing the gene expression profile data as input to a trained prediction model;
and outputting the survival period prediction result of the cancer patient to be detected.
Further, the prediction model is a Cox regression model.
Further, the Cox regression model is a LASSO Cox regression model.
Further, the formula of the prediction model isWherein N is the number of genes used for predicting prognosis, Expi is the expression level of each gene, and Ci is the regression coefficient of each gene; the genes are BIRC5, RNASE2 and THRB.
Further, the C1, C2 and C3 are respectively 0.425, 0.1117 and-0.7094.
The invention has the advantages and beneficial effects that:
according to the invention, the BIRC5, RNASE2 and/or THRB are/is selected as biomarkers, so that the prognosis of a renal cancer patient can be effectively predicted, and early intervention and early treatment can be realized.
Drawings
FIG. 1 is a graph of survival in the training set for BIRC5, RNASE2, and THRB in combination for predicting prognosis of lung adenocarcinoma;
FIG. 2 is a graph of survival demonstrating the combined prediction of prognosis of lung adenocarcinoma by BIRC5, RNASE2 and THRB;
FIG. 3 is a ROC plot of BIRC5, RNASE2 and THRB in training sets combined to predict prognosis of lung adenocarcinoma;
FIG. 4 is a ROC plot demonstrating the combined prediction of lung adenocarcinoma prognosis by concentration of BIRC5, RNASE2 and THRB.
Detailed Description
The present invention provides, in part, kits, genetic features, and methods of detecting such genetic features/biomarkers to perform analyses of renal cancer tissue samples, and in one aspect, the present invention provides genetic features related to renal cancer survival that can classify the risk of poor prognosis in an individual, helping guide physicians in selecting treatment strategies.
As used herein, "and/or" should be viewed as specifically disclosing each of the two specified features or components, with or without the other. For example, "a and/or B" will be considered a specific disclosure of each of (i) a, (ii) B, and (iii) a and B, as if each were individually listed herein.
As used herein, the terms "biomarker", "marker" and "genetic characteristic" are interchangeable and refer to a molecule that is differentially present in a sample taken from a subject with a good prognosis of renal cancer as compared to a comparable sample taken from a control subject, e.g., a subject with a poor prognosis of renal cancer. Thus, the biomarkers of the invention provide information about the likely course of kidney cancer and correlate with the prognosis of kidney cancer.
The term "biomarker" refers to any of the individual biomarkers described above, preferably BIRC5, RNASE2 or THRB, or any biomarker combination thereof.
In some embodiments, the genetic signature is capable of classifying the prognosis of the individual. As used herein, prognosis refers to prediction of medical outcome and can be used to determine a treatment or diagnostic work schedule based on metrics such as overall survival, renal cancer specific survival, recurrence-free (recurrence) survival, recurrence-free (relapse) survival, and distal recurrence-free survival.
In some embodiments, as understood by those of skill in the art, when the renal cancer prognostic genetic signature consists of the above-described genes, the method for performing the analysis may include measuring the expression of other genes (e.g., for normalization), but classifying the individual using only the genetic signature.
BIRC5 gene: baculoviral IAP repeat associating 5, with gene ID: 332 typical homo sapiens mRNA and protein sequences can be found in the NCBI database.
RNASE2 gene: ribonuclear A family member 2, with gene ID: 6036 typical homo sapiens mRNA and protein sequences can be found in NCBI databases.
THRB gene: thyoid hormon receiver beta, gene ID: 7068 typical homo sapiens mRNA and protein sequences can be found in NCBI databases.
Sample(s)
As used herein, "sample" may refer to a biological sample, typically a clinical sample, and includes, for example, blood and other bodily fluids, including but not limited to peripheral blood, serum, plasma, urine, and saliva; and solid tissue samples, such as biopsy specimens, particularly those containing cancer cells. In certain embodiments, a blood sample, such as a serum or plasma sample, is the most preferred type of sample to be used in the present methods. In general, the sample to be analyzed obtained from the subject is not part of the prognostic methods of the present invention.
The term "sample" also includes samples that have been manipulated or processed in any suitable manner after purchase, including, but not limited to, centrifugation, filtration, precipitation, dialysis, chromatography, treatment with reagents, washing, or enrichment of certain components of the sample, such as a cell population.
Biomarkers
As used herein, "biomarker" refers to a biological molecule present in an individual at different concentrations that can be used to predict the cancer status of the individual. Biomarkers can include, but are not limited to, nucleic acids, proteins, and variants and fragments thereof. A biomarker may be DNA comprising all or part of a nucleic acid sequence encoding the biomarker, or the complement of such a sequence. Biomarker nucleic acids useful in the present invention are considered to include DNA and RNA comprising all or part of any nucleic acid sequence of interest.
Gene expression
Herein, the term "level" is used interchangeably with the terms "amount" and "concentration" when applied to a biomarker, and may refer to either an absolute or relative amount of the biomarker.
The expression level of any of the biomarkers of the invention can be determined by a variety of techniques. In particular, expression at the nucleic acid level may be determined by measuring the amount of RNA, preferably mRNA or any other RNA species, representative of the biomarker in question, using methods well known in the art. Non-limiting examples of suitable methods include digital PCR and real-time (RT) quantitative or semi-quantitative PCR. Primers suitable for these methods can be readily designed by the skilled artisan.
In real-time pcr (qpcr), the reaction is characterized by the point in time during the cycle at which amplification of the target is first detected, rather than the amount of target accumulated over a fixed number of cycles. This point when a signal is first detected is called the threshold period (Ct). In some embodiments, the expression of gene signatures are quantified relative to each other by normalizing the expression of housekeeping genes by subtracting the Ct of the signature gene from the average Ct of the housekeeping genes.
Other suitable techniques for determining the expression level of any one of the biomarkers of the invention at the nucleic acid level include, but are not limited to, Fluorescence Activated Cell Sorting (FACS) and in situ hybridization.
Other non-limiting ways of measuring the amount of RNA, preferably mRNA or any other RNA species, representative of the biomarker in question include transcriptome methods, in particular DNA microarrays. Typically, when the amount of mRNA is to be determined, test and control mRNA samples are reverse transcribed and labeled to generate cDNA probes. The probes are then hybridized to an array of complementary nucleic acids immobilized on a solid support. The array is configured to know the sequence and location of each member of the array. Hybridization of a labeled probe to a particular array member indicates that the sample from which the probe was derived expresses the gene. Non-limiting examples of commercially available microarray systems include Affymetrix GeneChipTM and Illumina BeadChip.
Furthermore, bulk RNA sequencing, single cell RNA sequencing or cDNA sequencing, e.g. by Next Generation Sequencing (NGS) methods, may also be used to determine the expression level of any one of the biomarkers of the invention.
Changes in the modulation of the activity of the gene encoding the biomarker in question can be determined by epigenetic analysis, such as histone modification analysis, for example by chromatin immunoprecipitation followed by sequencing or quantitative PCR, or by quantifying the level of DNA methylation, for example by bisulfite sequencing or capture-based methods, at intergenic regulatory sites or gene regions of the biomarker in question.
It will be apparent to the skilled person that a variety of techniques can be used to determine the expression level of any one of the biomarkers of the invention at the protein level. Non-limiting examples of suitable methods include mass spectrometry-based quantitative proteomics techniques, such as Isobaric Tagging (iTRAQ) and label-free analysis of relative and absolute quantitation reagents, and Selective Reaction Monitoring (SRM) mass spectrometry and any other technique that targets proteomics. Furthermore, the level or amount of a protein marker can be determined, for example, by an immunoassay (e.g., ELISA or) Western blotting, spectrophotometry, enzymatic assay, ultraviolet assay, kinetic assay, electrochemical assay, colorimetric assay, turbidimetric assay, atomic absorption assay, flow cytometry, mass spectrometry flow cytometry or any combination thereof. Other suitable analytical techniques include, but are not limited to, liquid chromatography, such as high performance/High Pressure Liquid Chromatography (HPLC), gas chromatography, nuclear magnetic resonance spectroscopy, related techniques and combinations and mixtures thereof, such as tandem liquid chromatography-mass spectrometry (LC-MS).
The term "primer" as used herein refers to a nucleic acid fragment comprising 5 to 100 nucleotides, preferably 15 to 30 nucleotides, capable of initiating an enzymatic reaction (e.g., an enzymatic amplification reaction).
The term "probe" as used herein refers to a nucleic acid sequence comprising at least 5 nucleotides, e.g., 5 to 100 nucleotides, that hybridizes under specified conditions to an expression product of a target gene or an amplification product of the expression product to form a complex. The hybridization probes may also include labels for detection. Such labels include, but are not limited to, labels for fluorescent quantitative PCR or fluorescent in situ hybridization. In a preferred embodiment, the label may be FAM, HEX, VIC, Cy5, or the like. In another preferred embodiment, the label may be biotin, digoxigenin, or the like.
The term "antibody" as used herein is well known in the art and refers to a specific immunoglobulin directed against an antigenic site. The antibody of the present invention refers to an antibody that specifically binds to the biomarker protein of the present invention, and can be produced according to a conventional method in the art. Forms of antibodies include polyclonal or monoclonal antibodies, antibody fragments (such as Fab, Fab ', F (ab')2, and Fv fragments), single chain Fv (scfv) antibodies, multispecific antibodies (such as bispecific antibodies), monospecific antibodies, monovalent antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigen binding site of an antibody, and any other modified immunoglobulin molecule comprising an antigen binding site, so long as the antibody exhibits the desired biological binding activity.
The term "polypeptide" refers to a compound consisting of amino acids joined together by peptide bonds, including full-length or amino acid fragments of a polypeptide. The amount of polypeptide encoded by the gene can be normalized to the amount of total protein in the sample or the amount of polypeptide encoded by the housekeeping gene.
Prognosis
As used herein, the term "prognosis" refers to the likely course of the disease or clinical outcome, while the expressions "anticipation", "making a prognosis", "determining a prognosis", etc., refer to the prediction of the future progression of the renal cancer.
As used herein, the terms "good prognosis" and "positive prognosis" refer to survival that may be statistically significantly prolonged compared to the median outcome of the disease or to the survival of a subject with a poor prognosis, e.g., prolonged overall survival, prolonged disease-free survival, prolonged relapse-free survival or prolonged progression-free survival.
As used herein, the term "poor prognosis" refers to survival that may be statistically significantly reduced, e.g., reduced overall survival, disease-free survival, relapse-free survival or progression-free survival, as compared to a subject with a good prognosis.
According to the present invention, in a biological sample obtained from a subject who is to be prognosticated for kidney cancer, prognosis is performed based on the detected level of a biomarker associated with the prognosis of kidney cancer. This is also meant to include situations where the prognosis is not finalized but further testing is required. In such embodiments, the method does not itself determine the prognosis of the subject's kidney cancer, but may indicate that further testing is required or would be beneficial. Thus, the present method may be combined with one or more other methods to ultimately determine a prognosis. Such other methods are well known to those skilled in the art and include, but are not limited to, biopsy, molecular characterization of tumors, computed tomography, magnetic resonance imaging, and positron emission tomography, as well as monitoring the level of carcinoembryonic antigen (CEA). Other predictive markers that may be used in combination with the present invention include, but are not limited to, molecular profiling of tumors, examining the chromosomal stability of tumors (microsatellite stability (MSS) and microsatellite instability (MSI)).
In some embodiments, the methods of the invention for prognosing kidney cancer in a subject suffering from kidney cancer may further comprise a therapeutic intervention. Once a subject is identified as having a given likely outcome of a disease, he/she may be subjected to appropriate therapeutic intervention, such as chemotherapy. In such embodiments, the invention can also be configured as a method of treating a renal cancer in a subject in need thereof, wherein the method comprises prognosing the renal cancer as described above, and administering one or more suitable chemotherapeutic agents to the subject.
The invention provides a life cycle prediction device and computer equipment. As described above, it can be understood by those skilled in the art that all or part of the processes of the methods of the above embodiments can be implemented by a computer program, which can be stored in a non-volatile computer readable storage medium, to instruct related hardware, and when executed, the computer program can include the processes of the embodiments of the methods. Any reference to memory, storage, database, or other medium used in the embodiments provided herein may include non-volatile and/or volatile memory. Non-volatile memory can include read-only memory (ROM), Programmable ROM (PROM), Electrically Programmable ROM (EPROM), Electrically Erasable Programmable ROM (EEPROM), or flash memory. Volatile memory can include Random Access Memory (RAM) or external cache memory. By way of illustration and not limitation, RAM is available in a variety of forms, such as Static RAM (SRAM), Dynamic RAM (DRAM), Synchronous DRAM (SDRAM), Double Data Rate SDRAM (DDRSDRAM), Enhanced SDRAM (ESDRAM), Synchronous Link DRAM (SLDRAM), Rambus Direct RAM (RDRAM), direct memory bus dynamic RAM (DRDRAM), and memory bus dynamic RAM (RDRAM).
The technical features of the above embodiments can be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the above embodiments are not described, but should be considered as the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The computer according to the present invention is a computing device capable of automatically performing numerical calculation and/or information processing according to instructions set or stored in advance, and the hardware thereof may include at least one memory, at least one processor, and at least one communication bus. Wherein the communication bus is used for realizing connection communication among the elements. The processor may include, but is not limited to, a microprocessor. Computer hardware may also include Application Specific Integrated Circuits (ASICs), Programmable gate arrays (FPGAs), Digital Signal Processors (DSPs), embedded devices, etc. The computer may also include a network device and/or a user device. Wherein the network device includes, but is not limited to, a single network server, a server group consisting of a plurality of network servers, or a Cloud Computing (Cloud Computing) -based Cloud consisting of a large number of hosts or network servers, wherein Cloud Computing is one of distributed Computing, a super virtual computer consisting of a collection of loosely coupled computers.
The computing device may be, but is not limited to, any terminal such as a personal computer, a server, etc. capable of human-computer interaction with a user through a keyboard, a touch pad, a voice control device, etc. The computing device herein may also include a mobile terminal, which may be, but is not limited to, any electronic device capable of human-computer interaction with a user through a keyboard, a touch pad, or a voice control device, for example, a tablet computer, a smart phone, a Personal Digital Assistant (PDA), a smart wearable device, and other terminals. Networks in which the computing device is located include, but are not limited to, the internet, wide area networks, metropolitan area networks, local area networks, Virtual Private Networks (VPNs), and the like.
The memory is for storing program code. The Memory may be a circuit without a physical form and having a Memory function in an integrated circuit, such as a RAM (Random-Access Memory), a fifo (first InFirst out), and the like. Alternatively, the memory may be a memory in a physical form, such as a memory bank, a TF Card (Trans-flash Card), a smart media Card (smart media Card), a secure digital Card (secure digital Card), a flash memory Card (flash Card), and so on.
The processor may include one or more microprocessors, digital processors. The processor may call program code stored in the memory to perform the associated functions. For example, the respective modules are program codes stored in the memory and executed by the processor to implement the above-described method. The processor is also called a Central Processing Unit (CPU), and may be an ultra-large scale integrated circuit, which is an operation Core (Core) and a Control Core (Control Unit).
It should be noted that, for simplicity of description, the above-mentioned method embodiments are described as a series of acts or combination of acts, but those skilled in the art will recognize that the present invention is not limited by the order of acts, as some steps may occur in other orders or concurrently in accordance with the invention. Further, those skilled in the art will also appreciate that the embodiments described in the specification are presently preferred and that no acts or modules are necessarily required to implement the invention.
The following detailed description of embodiments of the present application will be made with reference to the accompanying drawings. It should be understood that the detailed description and specific examples, while indicating the present application, are given by way of illustration and explanation only, and are not intended to limit the present application.
Example biomarkers associated with renal cancer prognosis
1. Data download
Public gene expression data and complete clinical annotations of renal clear cell carcinoma were searched in a cancer genomic profile database (TCGA), excluding samples lacking survival or having a survival of 0, with a total number of 531 included samples, randomly divided into 371 as training set and 160 as validation set.
2. Data normalization
RNA-seq data for TCGA were normalized using Voom method, genes were annotated using the tidyverse package in R, de-duplication averages were pooled, and RNA sequencing data for gene expression (FPKM values) were converted to transcripts with million per kilobase (TPM) values.
3. Screening for immune-related genes
The immune-related genes were from the immport database (https:// www.immport.org/home). Genes co-existing in the immport database with TCGA were screened.
4. One-factor Cox analysis
And (3) carrying out single-factor Cox analysis on the genes in the training set and the verification set by using a survivval package and a survivor package in the R, and screening the genes related to the survival of the kidney cancer patient in the two data sets, wherein the gene with the P <0.001 is considered to have an influence on the survival of the kidney cancer patient.
5. LASSO Cox regression analysis
And performing LASSO Cox regression analysis to construct a LASSO regression model. Using the data of the training set, performing regression analysis modeling on the data of the training set by using a glmnet packet and a survivval packet in the R language, and outputting a correlation coefficient and a risk score (risk score) of a prediction model, wherein seed is set to 2.
And calculating the risk score of each sample by using the same formula when verification is carried out in the verification set, dividing all samples into a high risk group and a low risk group according to the median of the risk score, and further carrying out survival analysis.
6. Survival Curve analysis
The R software 'survivval', 'surviviner' and 'ggplot 2' packages are adopted to carry out survival analysis on the renal cancer patients in the high risk group and the low risk group of the training set and the verification set, and the survival curves are drawn, and the inter-group difference comparison is carried out through log-rank test.
7. ROC curve analysis
In order to evaluate the accuracy of the prognosis model in predicting the kidney cancer prognosis, the R software 'survivval' and 'timeROC' packages are adopted to detect the prognosis efficiencies of the biomarkers for 1 year, 3 years and 5 years by using time-dependent ROC curves, the significance of the difference between various groups of ROC curves is detected by using a self-sampling method, and the P <0.05 is considered to have statistical difference.
8. Results
The results of the gene one-way Cox regression analysis and LASSO coefficients in the risk scores are shown in table 1.
TABLE 1 genes associated with prognosis
Risk score 0.425 × exppbirc 5+0.1117 × expnase 2-0.7094 × exphrb.
Renal cancer patients were analyzed in the high risk group (high score) and the low risk group (low score) according to the median of the risk scores, and by KM survival analysis, the difference in survival time of the two groups was compared, and it was found that the cumulative survival rate of patients in the high risk group was significantly lower than that in the low risk group. Consistent with the results of the training set (fig. 1), the cumulative survival of patients in the high risk group was significantly lower than that in the low risk group (fig. 2).
The renal cancer patients in the training set and the verification set are subjected to prognostic ROC curve analysis, and the results show that the risk score prognostic model has better distinguishing performance on the prognosis of the renal cancer patients (FIG. 3 and FIG. 4).
In conclusion, the survival/prognosis of kidney cancer can be predicted based on the gene of the present invention.
The preferred embodiments of the present application have been described in detail with reference to the accompanying drawings, however, the present application is not limited to the details of the above embodiments, and many simple modifications may be made to the technical solution of the present application within the technical idea of the present application, and these simple modifications are within the scope of protection of the present application.
It should be noted that, in the foregoing embodiments, various features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described in the present application.
In addition, any combination of the various embodiments of the present application can be made, and the same should be considered as the disclosure of the present application as long as the idea of the present application is not violated.
Claims (10)
1. A biomarker panel for the prognosis of kidney cancer, wherein the biomarker panel comprises BIRC5, RNASE2 and/or THRB.
2. Use of a reagent for detecting the biomarker profile of claim 1 in a sample for the preparation of a diagnostic product for the prognosis of renal cancer.
3. The use of claim 2, wherein the agent comprises an agent for detecting the level of expression of a biomarker in a sample by digital imaging techniques, protein immunization techniques, dye techniques, nucleic acid sequencing techniques, nucleic acid hybridization techniques, chromatography techniques, mass spectrometry techniques.
4. The use according to claim 2, wherein the sample is selected from the group consisting of: peripheral blood samples, serum samples, plasma samples, urine samples, saliva samples, and tissue samples.
5. A diagnostic product for the prognosis of renal cancer, comprising reagents for detecting the biomarker panel of claim 1;
preferably, the diagnostic product comprises a chip, a kit.
6. The diagnostic product of claim 5, wherein the reagents comprise reagents that detect the amount of RNA transcribed from the genes of the biomarker panel;
preferably, the reagent is a reagent that detects the amount of mRNA transcribed from the biomarker population;
preferably, the reagent is a reagent for detecting the amount of cDNA complementary to mRNA transcribed from the gene;
preferably, the reagents comprise probes or primers;
preferably, the diagnostic product further comprises a total RNA extraction reagent, a reverse transcription reagent and/or a secondary sequencing reagent.
7. The diagnostic product of claim 5, wherein the agent is an agent that detects the amount of polypeptides/proteins encoded by the biomarker panel genes;
preferably, the agent is an antibody, an antibody fragment or an affinity protein.
8. A kidney cancer survival prediction device, comprising:
a data acquisition module for acquiring the gene expression profile data of the biomarker group of claim 1 of a cancer patient to be tested;
a prediction module to provide the gene expression profile data as input to a trained prediction model trained to predict the survival of a cancer patient based on gene expression profile data of the cancer patient;
the prediction result acquisition module is used for acquiring the output of the prediction model to obtain the life cycle prediction result of the cancer patient to be detected;
preferably, the prediction model is a Cox regression model;
preferably, the Cox regression model is a LASSOCox regression model;
preferably, theWherein N is the number of genes for predicting prognosis, Expi is the expression level of each gene, and Ci is the regression coefficient of each gene; when the risk score is higher, the patient has a poor prognosis; when the risk score is low, the patient prognosis is good;
preferably, the genes are BIRC5, RNASE2 and THRB;
preferably, the C1, C2, C3 are 0.425, 0.1117, -0.7094, respectively.
9. A computer device comprising a memory and a processor, the memory storing a program, the processor implementing the method when executing the program:
obtaining gene expression profiling data of the biomarker panel of claim 1 for a cancer patient to be tested;
providing the gene expression profile data as input to a trained prediction model;
outputting the survival period prediction result of the cancer patient to be detected;
preferably, the prediction model is a Cox regression model;
preferably, the Cox regression model is a LASSOCox regression model;
preferably, theWherein N is the number of genes used for predicting prognosis, Expi is the expression level of each gene, Ci is the regression coefficient of each gene, and when the risk score is higher, the prognosis of the patient is poor; when the risk score is low, the patient prognosis is good;
preferably, the genes are BIRC5, RNASE2 and THRB;
preferably, the C1, C2, C3 are 0.425, 0.1117, -0.7094, respectively.
10. A computer-readable storage medium on which a program is stored, the program, when executed, implementing a method of:
obtaining gene expression profiling data of the biomarker panel of claim 1 for a cancer patient to be tested;
providing the gene expression profile data as input to a trained prediction model;
outputting the survival period prediction result of the cancer patient to be detected;
preferably, the prediction model is a Cox regression model;
preferably, the Cox regression model is a LASSOCox regression model;
preferably, theWherein N is the number of genes for predicting prognosis, Expi is the expression level of each gene, and Ci is the regression coefficient of each gene; the genes are BIRC5, RNASE2 and THRB;
preferably, the C1, C2, C3 are 0.425, 0.1117, -0.7094, respectively.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110731571.2A CN113430270A (en) | 2021-06-30 | 2021-06-30 | Application of immune related gene in renal cancer prognosis prediction |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110731571.2A CN113430270A (en) | 2021-06-30 | 2021-06-30 | Application of immune related gene in renal cancer prognosis prediction |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113430270A true CN113430270A (en) | 2021-09-24 |
Family
ID=77757844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110731571.2A Pending CN113430270A (en) | 2021-06-30 | 2021-06-30 | Application of immune related gene in renal cancer prognosis prediction |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113430270A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116844685A (en) * | 2023-07-03 | 2023-10-03 | 广州默锐医药科技有限公司 | Immunotherapeutic effect evaluation method, device, electronic equipment and storage medium |
-
2021
- 2021-06-30 CN CN202110731571.2A patent/CN113430270A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116844685A (en) * | 2023-07-03 | 2023-10-03 | 广州默锐医药科技有限公司 | Immunotherapeutic effect evaluation method, device, electronic equipment and storage medium |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113444798A (en) | Renal cancer survival risk biomarker group, diagnosis product and application | |
JP2015536667A (en) | Molecular diagnostic tests for cancer | |
EA025926B1 (en) | Molecular diagnostic test for cancer | |
JP2016536001A (en) | Molecular diagnostic test for lung cancer | |
JP2016531579A (en) | Molecular diagnostic test for esophageal cancer | |
JP2015535176A (en) | A novel method for predicting overall and relapse-free survival in hepatocellular carcinoma | |
CN113234830B (en) | Product for lung cancer diagnosis and application | |
WO2012009382A2 (en) | Molecular indicators of bladder cancer prognosis and prediction of treatment response | |
CN114875149A (en) | Application of reagent for detecting biomarkers in preparation of product for predicting gastric cancer prognosis | |
CN114990215A (en) | Application of microRNA biomarker in lung cancer diagnosis or prognosis prediction | |
CN113430270A (en) | Application of immune related gene in renal cancer prognosis prediction | |
CN113444801A (en) | Kidney cancer prognosis detection marker and related diagnosis product thereof | |
KR20190143058A (en) | Method of predicting prognosis of brain tumors | |
CN113444799A (en) | Immune-related genes for identifying poor prognosis of renal cancer | |
CN113388684A (en) | Use of biomarkers for predicting the prognosis of renal cancer | |
KR102104233B1 (en) | Method of predicting prognosis of brain tumors | |
US20210285053A1 (en) | L1td1 as predictive biomarker of colon cancer | |
US20180274037A1 (en) | Novel biomarkers for pancreatic diseases | |
CN115521985A (en) | Marker combination of infiltrating CD8+ T cells and application thereof | |
CN113337610A (en) | Diagnostic marker as prognosis of renal cancer | |
CN113337612A (en) | Kidney cancer prognosis related biomarker and application thereof | |
CN113337611A (en) | Biomarker-based diagnostic products and devices for monitoring the prognosis of renal cancer | |
CN113430271A (en) | Biomarkers for predicting prognosis of renal cancer patients | |
CN113444800A (en) | Application of gene group as co-prognostic factor in renal cancer prognosis detection | |
CN113999911A (en) | Product for predicting sensitivity of melanoma immunotherapy drug and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210924 |
|
RJ01 | Rejection of invention patent application after publication |